BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-4.07%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$8.61B
AUM Growth
+$8.61B
(-11%)
Cap. Flow
-$378M
Cap. Flow
% of AUM
-4.39%
Top 10 Holdings %
Top 10 Hldgs %
30.78%
Holding
207
New
16
Increased
51
Reduced
80
Closed
30
Top Buys
| 1 |
Outset Medical
OM
|
$66.1M |
| 2 |
Boston Scientific
BSX
|
$42.1M |
| 3 |
CareDx
CDNA
|
$31.2M |
| 4 |
Pacific Biosciences
PACB
|
$30.3M |
| 5 |
Aurinia Pharmaceuticals
AUPH
|
$29.8M |
Top Sells
| 1 |
Biogen
BIIB
|
$106M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$81.3M |
| 3 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
$75.3M |
| 4 |
Danaher
DHR
|
$68.9M |
| 5 |
Humana
HUM
|
$68M |
Sector Composition
| 1 | Healthcare | 98.39% |
| 2 | Industrials | 0.69% |
| 3 | Energy | 0.03% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vertex Pharmaceuticals
VRTX
$100B
| $386M | 4.49% | 1,480,253 -311,508 | -17% | -$81.3M |
|
2
Ionis Pharmaceuticals
IONS
$6.8B
| $367M | 4.27% | 9,918,073 -437,050 | -4% | -$16.2M |
|
3
argenx
ARGX
$43.6B
| $301M | 3.49% | 953,238 -43,800 | -4% | -$13.8M |
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $283M | 3.29% | 3,023,451 -157,100 | -5% | -$14.7M |
|
5
Moderna
MRNA
$9.37B
| $282M | 3.28% | 1,639,349 -69,900 | -4% | -$12M |
|
6
Incyte
INCY
$16.5B
| $226M | 2.63% | 2,847,400 -109,600 | -4% | -$8.7M |
|
|
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $210M | 2.44% | 3,429,619 -199,300 | -5% | -$12.2M |
|
8
Elevance Health
ELV
$71.8B
| $202M | 2.35% | 411,637 -43,657 | -10% | -$21.4M |
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $201M | 2.33% | 1,229,563 -105,577 | -8% | -$17.2M |
|
10
Abbott
ABT
$231B
| $192M | 2.23% | 1,622,927 -122,874 | -7% | -$14.5M |
|
11
Intuitive Surgical
ISRG
$170B
| $187M | 2.17% | 620,068 +35,605 | +6% | +$10.7M |
|
|
12
Boston Scientific
BSX
$156B
| $173M | 2.01% | 3,913,947 +949,916 | +32% | +$42.1M |
|
13
UnitedHealth
UNH
$281B
| $156M | 1.81% | 305,701 -6,580 | -2% | -$3.36M |
|
14
Arvinas
ARVN
$568M
| $147M | 1.7% | 2,179,253 -54,150 | -2% | -$3.64M |
|
15
Fate Therapeutics
FATE
$120M
| $139M | 1.61% | 3,576,486 -199,250 | -5% | -$7.72M |
|
16
Tandem Diabetes Care
TNDM
$845M
| $130M | 1.51% | 1,116,508 +167,251 | +18% | +$19.4M |
|
|
AXNX
17
DELISTED
Axonics, Inc. Common Stock
AXNX
| $128M | 1.49% | 2,049,205 +177,191 | +9% | +$11.1M |
|
18
Agios Pharmaceuticals
AGIO
$2.19B
| $120M | 1.4% | 4,129,292 -220,000 | -5% | -$6.4M |
|
19
DexCom
DXCM
$29.5B
| $120M | 1.4% | 234,900 -253 | -0.1% | -$129K |
|
20
Stryker
SYK
$150B
| $118M | 1.37% | 440,225 +18,341 | +4% | +$4.9M |
|
21
Jazz Pharmaceuticals
JAZZ
$7.75B
| $118M | 1.36% | 754,981 -131,873 | -15% | -$20.5M |
|
22
Relay Therapeutics
RLAY
$619M
| $117M | 1.36% | 3,918,962 -187,000 | -5% | -$5.6M |
|
23
Edwards Lifesciences
EW
$47.8B
| $107M | 1.25% | 912,785 -8,400 | -0.9% | -$989K |
|
24
Insulet
PODD
$23.9B
| $106M | 1.23% | 398,189 +15,466 | +4% | +$4.12M |
|
25
Becton Dickinson
BDX
$55.3B
| $105M | 1.22% | 396,405 -59,007 | -13% | -$15.7M |
|